PMID- 33619633 OWN - NLM STAT- MEDLINE DCOM- 20210819 LR - 20220218 IS - 1436-3771 (Electronic) IS - 1432-6981 (Print) IS - 1432-6981 (Linking) VI - 25 IP - 9 DP - 2021 Sep TI - Dental and periodontal disease in patients with inflammatory bowel disease. PG - 5273-5280 LID - 10.1007/s00784-021-03835-6 [doi] AB - OBJECTIVES: Although bowel symptoms are often predominant, inflammatory bowel disease (IBD) patients can have several oral manifestations. The aim of this study was to investigate the prevalence of dental caries and periodontal disease in patients with Crohn's disease (CD) and ulcerative colitis (UC) compared to an age and gender-matched control group of patients without IBD. MATERIAL AND METHODS: The DMFT (Decayed, Missing, Filled Teeth) scores and the DPSI (Dutch Periodontal Screening Index) of 229 IBD patients were retrieved from the electronic health record patient database axiUm at the Academic Centre for Dentistry Amsterdam (ACTA) and were compared to the DMFT scores and DPSI from age and gender-matched non-IBD patients from the same database. RESULTS: The total DMFT index was significantly higher in the IBD group compared to the control group. When CD and UC were analyzed separately, a statistically significant increased DMFT index was observed in CD patients but not in UC patients. The DPSI did not differ significantly between the IBD and non-IBD groups for each of the sextants. However, in every sextant, IBD patients were more frequently edentulous compared to the control patients. CONCLUSION: CD patients have significantly more dental health problems compared to a control group. Periodontal disease did not differ significantly between IBD and non-IBD groups as determined by the DPSI. CLINICAL RELEVANCE: It is important that IBD patients and physicians are instructed about the correlation between their disease and oral health problems. Strict oral hygiene and preventive dental care such as more frequent checkups should be emphasized by dental clinicians. CI - (c) 2021. The Author(s). FAU - Tan, Christopher X W AU - Tan CXW AUID- ORCID: 0000-0002-0819-0238 AD - Department of Oral and Maxillofacial Surgery/Oral Pathology, Amsterdam University Medical Centre/Academic Centre for Dentistry Amsterdam (ACTA), PO Box 7057, 1007 MB, Amsterdam, The Netherlands. c.tan@amsterdamumc.nl. FAU - Brand, Henk S AU - Brand HS AD - Department of Oral Biochemistry, Academic Centre for Dentistry Amsterdam (ACTA), Amsterdam, The Netherlands. FAU - Kalender, Bilgin AU - Kalender B AD - Department of Oral Biochemistry, Academic Centre for Dentistry Amsterdam (ACTA), Amsterdam, The Netherlands. FAU - De Boer, Nanne K H AU - De Boer NKH AD - Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre, VU University, AGEM Research Institute, Amsterdam, The Netherlands. FAU - Forouzanfar, Tymour AU - Forouzanfar T AD - Department of Oral and Maxillofacial Surgery/Oral Pathology, Amsterdam University Medical Centre/Academic Centre for Dentistry Amsterdam (ACTA), PO Box 7057, 1007 MB, Amsterdam, The Netherlands. FAU - de Visscher, Jan G A M AU - de Visscher JGAM AD - Department of Oral and Maxillofacial Surgery/Oral Pathology, Amsterdam University Medical Centre/Academic Centre for Dentistry Amsterdam (ACTA), PO Box 7057, 1007 MB, Amsterdam, The Netherlands. LA - eng PT - Journal Article DEP - 20210223 PL - Germany TA - Clin Oral Investig JT - Clinical oral investigations JID - 9707115 MH - *Colitis, Ulcerative/complications/epidemiology MH - *Dental Caries/epidemiology MH - Humans MH - *Inflammatory Bowel Diseases/complications/epidemiology MH - *Periodontal Diseases/complications/epidemiology MH - Periodontal Index PMC - PMC8370899 OTO - NOTNLM OT - Crohn's disease OT - DMFT (Decayed OT - DPSI (Dutch Periodontal Screening Index) OT - Filled Teeth) OT - Inflammatory bowel disease OT - Missing OT - Oral health OT - Ulcerative colitis COIS- N.K.H. de Boer served as a speaker for AbbVie and MSD and as a consultant and/or principal investigator for TEVA Pharma VB and Takeda. He received (unrestricted) research funding from MLDS, TEVA Pharma VB, and Takeda, all outside the submitted work. All other authors have nothing to declare. EDAT- 2021/02/24 06:00 MHDA- 2021/08/20 06:00 PMCR- 2021/02/23 CRDT- 2021/02/23 06:16 PHST- 2020/09/23 00:00 [received] PHST- 2021/02/08 00:00 [accepted] PHST- 2021/02/24 06:00 [pubmed] PHST- 2021/08/20 06:00 [medline] PHST- 2021/02/23 06:16 [entrez] PHST- 2021/02/23 00:00 [pmc-release] AID - 10.1007/s00784-021-03835-6 [pii] AID - 3835 [pii] AID - 10.1007/s00784-021-03835-6 [doi] PST - ppublish SO - Clin Oral Investig. 2021 Sep;25(9):5273-5280. doi: 10.1007/s00784-021-03835-6. Epub 2021 Feb 23.